LEO Pharma’s Anzupgo® Meets Phase 3 Endpoint in China for Chronic Hand Eczema LEO Pharma A/S, a global leader in medical dermatology, has announced positive results from the double-blind treatment period of the DELTA China trial. This phase 3 clinical…
Latus Bio Presents Preclinical Data Supporting Its Huntington’s Disease Gene Therapy Program Latus Bio, Inc. (Latus), a biotechnology company pioneering advancements in adeno-associated virus (AAV) gene therapy, is pleased to announce the presentation of new preclinical data supporting its investigational…
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance GeneDx Holdings Corp. (Nasdaq: WGS), a leader in leveraging genomic insights to drive improved health outcomes, has announced its financial results for the fourth quarter and…
Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug Abcuro, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat autoimmune diseases and cancer by precisely modulating cytotoxic T cells, has successfully closed a $200 million…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has successfully closed its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT), which was initially announced on November 26, 2024. The closing of this highly anticipated transaction was contingent upon the expiration or…
Aurion Biotech, Inc. (Aurion), a company dedicated to restoring vision for millions through transformative regenerative therapies, has announced the appointment of Donald Munoz as Chief Financial Officer (CFO). Munoz will report directly to Greg Kunst, Chief Executive Officer (CEO), and…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced the presentation of novel data on long-term prophylaxis (LTP) and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting, held in Waimea, HI, from February 9-13, 2025. Addressing…
Nutriband Secures U.S. Patent Approval for Aversa™ Transdermal Abuse Deterrent Technology Nutriband a pharmaceutical company specializing in the development of prescription transdermal products, recently announced that it has received a Notice of Allowance from the United States Patent and Trademark…
Know Labs Technology Licensing (KTL) Announces Official Client Partnership Know Labs is pleased to announce the official launch of its structured client engagement process for Know Labs Technology Licensing (KTL), ensuring a seamless pathway for corporations, universities, and research institutions…
GoodRx the leading prescription savings platform in the United States, has announced the appointment of Christopher A. McGinnis as its new Chief Financial Officer (CFO), effective February 4, 2025. McGinnis, a seasoned financial executive with three decades of experience in…
Announces Cencora Reports Strong Fiscal 2025 First Quarter Results, Expects Continued Growth and Strategic Expansion Announces Cencora has announced its results for the first quarter of fiscal year 2025, reporting robust growth and strategic expansion despite challenges in some market…
Medications from Miist Therapeutics Secures $7M in Funding to Develop Fast-Acting Treatments Medications Miist Therapeutics, a trailblazing company focused on the development of physics-based inhaled medicines, has announced that it has secured $7 million in seed funding from a group…